SCHEMBL1570183

SCHEMBL1570183

O=[N+]([O-])c1cc(-c2noc(-c3cc(C(F)(F)F)c[n+]([O-])c3)n2)cc(O)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.50
TTR P02766 1/20 0.42
S1PR1 P21453 5/20 0.41
MAPT P10636 2/20 0.38
S1PR3 Q99500 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
CHUK O15111 1/20 0.35
TXNRD1 Q16881 1/20 0.35
NOX4 Q9NPH5 1/20 0.35
POLB P06746 2/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447492 0.84 TTR (0.41) COMTTTRMAPTMEN1KMT2A
SCHEMBL1446916 0.84 COMT (0.39) COMTTTRMAPTMEN1KMT2A
SCHEMBL1447372 0.83 TTR (0.43) COMTTTRMAPTMEN1KMT2A
SCHEMBL1447359 0.83 COMT (0.49) COMTTTRS1PR1MAPTS1PR3
SCHEMBL2691043 0.83 TTR (0.39) COMTTTRMAPTMEN1KMT2A
SCHEMBL3582149 0.81 COMT (0.49) COMTTTRS1PR1MAPTS1PR3
SCHEMBL1447041 0.81 COMT (0.56) COMTTTRMAPTMEN1KMT2A
SCHEMBL1447362 0.81 COMT (0.49) COMTTTRS1PR1MAPTNPC1
SCHEMBL1447301 0.79 COMT (0.46) COMTTTRS1PR1MAPTMEN1
SCHEMBL31681295 0.79 COMT (0.58) COMTTTRMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276963-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS BIAL - PORTELA & CA, S.A. (PT) 2025-09-04 US disclosed
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2022-12-08 US disclosed
EP-3831382-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS Bial-Portela & CA, S.A. (PT) 2021-06-09 EP disclosed
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2020-04-02 US disclosed
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2019-07-02 US disclosed
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & COMPANHIA, S.A. (PT) 2017-12-21 US disclosed
US-9550759-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2017-01-24 US disclosed
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2015-03-12 US disclosed
US-8907099-B2 Nitrocatechol derivatives as COMT inhibitors BIAL-PORTELA & CA, S.A. (PT) 2014-12-09 US disclosed
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA., S.A. (PT) 2012-08-02 US disclosed
US-8168793-B2 Nitrocatechol derivatives as COMT inhibitors PORTELA & CA., S.A. (PT) 2012-05-01 US disclosed
EP-2307020-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS Bial-Portela & CA, S.A. (PT) 2011-04-13 EP disclosed
WO-2010014025-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS BIAL - PORTELA & CA., S.A. (PT) 2010-02-04 WO disclosed
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors PORTELA & CA., S.A. (PT) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885TTR 2183/4885S1PR1 4343/4885
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885TTR 2183/4885S1PR1 4343/4885
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885TTR 2123/4885S1PR1 4357/4885
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors COMT, PNMT, OPRK1 COMT 1/4885TTR 2183/4885S1PR1 4343/4885
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors COMT, PNMT, OPRK1 COMT 1/4885TTR 2183/4885S1PR1 4343/4885
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885TTR 2123/4885S1PR1 4357/4885
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885TTR 2183/4885S1PR1 4343/4885
US-20250276963-A1 ADMINISTRATION REGIME FOR NITROCATECHOLS HCRTR1, MTNR1A, CHRM1 COMT 19/4885TTR 1445/4885S1PR1 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.